ENAGenomicsSehgal Lab, Hematology, The Ohio State Universityhttps://www.ebi.ac.uk/ena/browser/view/PRJNA574837Homo sapiensTo understand the acquired resistance mechanism in DLBCL the cell lines (OCI-Ly1, Oci-Ly10 and HBL-1) were treated with Ibrutinib over time to generate resistant clone. Overall design: The gene expression profile was measured in parental and Ibrutinib resistant clones after 8 months. All the gene expression data for parental is labeled in triplicate marked (A-C) and for the ibrutinib resitance is labeled as (Res).xref:PubMed:33946867xref:PubMed:32926124ENAfalseGene expression signatures for Ibrutinib resistance in Diffuse Large B-cell Lymphoma (ABC-DLBCL)Gene expression signatures for Ibrutinib resistance in Diffuse Large B-cell Lymphoma (ABC-DLBCL)2025-09-242019-11-03PRJNA574837GSE13812696063292612433946867